RemeGen In-Licenses Pan-RAS(ON) Inhibitor in RMB 4.92bn Deal

RemeGen has entered a licence agreement with Chinese compatriot Rongchang Pharmaceutical to obtain global exclusive rights to a pan-RAS(ON) small-molecule inhibitor programme, including lead compound RCZY-690, across all indications and uses. RemeGen will pay RMB 50 million (USD 7.5 million) upfront and up to RMB 4.87 billion (USD 730 million) in milestones, plus 3% to 7% tiered royalties on annual net sales, bringing a broadly mutant-selective RAS asset into its oncology portfolio.
Pan-RAS(ON) inhibitors aim to lock the active conformation of KRAS, NRAS and HRAS variants simultaneously, addressing the coverage gaps left by existing mutant-specific drugs in pancreatic, colorectal (CRC) and non-small-cell lung (NSCLC) cancers.
RCZY-690 already cleared clinical trial initiation in August and dosed its first patient in September, giving RemeGen a fast-starting solid-tumour programme.

Daily News
Incyte's Povorcitinib Becomes First Daily Pill for HS in EU
2026-11-18
Lilly Backs Stipple Bio in Up to USD 5.9bn Oncology Target-Discovery Deal
2026-11-18
CataX AI Raises RMB 40 Million Seed Round to Reinvent Clinical Development
2026-11-17
INFevo Closes Record Virtual-Cell Financing to Build Recursive Discovery Platform
2026-11-17
J&J to Acquire Ollin for Up to USD 3.325bn for VEGF-A×Ang2 BsAb
2026-11-17
Latest Report
AI- in-BD- Portfolio
Details